Featuring an interview with Dr Wassim Abida, including the following topics:
- Comparing the clinical relevance of BRCA1 and BRCA2 mutations in prostate cancer (0:00)
- Relevance and interpretation of LOH (loss of heterozygosity) scores (4:37)
- Incidence and clinical relevance of PALB2 mutations; role of genetic counseling in the care of patients with prostate cancer (9:33)
- Key considerations surrounding toxicities associated with PARP inhibitors (15:25)
- Potential role of saruparib; evolving nomenclature in prostate cancer (22:36)
- Approach to newly diagnosed metastatic prostate cancer (26:16)
- Clinical relevance of PSMA-targeted PET imaging results (29:49)
- Case: A man in his mid 70s with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA alteration receives olaparib/abiraterone/prednisone upon relapse (32:15)
- Combining PARP inhibitors with other DNA repair inhibitors; insights on the PSMAddition trial (37:14)
- Case: A man in his mid 60s with metastatic prostate adenocarcinoma and a BRCA germline mutation receives niraparib/abiraterone/prednisone (43:17)
- Case: A man in his early 60s with mCRPC and CDK12 mutations receives talazoparib/enzalutamide (45:54)